Research ExplorerPublicationsLong-term follow-up of gastric MALT lymphoma after Helicobac...

Long-term follow-up of gastric MALT lymphoma after Helicobacter pylori eradication

Standard

Long-term follow-up of gastric MALT lymphoma after Helicobacter pylori eradication. / Wündisch, Thomas; Thiede, Christian; Morgner, Andrea; Dempfle, Astrid; Günther, Annette; Liu, Hongxiang; Ye, Hongtao; Du, Ming-Qing; Kim, Theo D; Bayerdörffer, Ekkehard; Stolte, Manfred; Neubauer, Andreas.

In: J CLIN ONCOL, Vol. 23, No. 31, 01.11.2005, p. 8018-24.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Wündisch, T, Thiede, C, Morgner, A, Dempfle, A, Günther, A, Liu, H, Ye, H, Du, M-Q, Kim, TD, Bayerdörffer, E, Stolte, M & Neubauer, A 2005, 'Long-term follow-up of gastric MALT lymphoma after Helicobacter pylori eradication', J CLIN ONCOL, vol. 23, no. 31, pp. 8018-24. https://doi.org/10.1200/JCO.2005.02.3903

APA

Wündisch, T., Thiede, C., Morgner, A., Dempfle, A., Günther, A., Liu, H., Ye, H., Du, M-Q., Kim, T. D., Bayerdörffer, E., Stolte, M., & Neubauer, A. (2005). Long-term follow-up of gastric MALT lymphoma after Helicobacter pylori eradication. J CLIN ONCOL, 23(31), 8018-24. https://doi.org/10.1200/JCO.2005.02.3903

Vancouver

Wündisch T, Thiede C, Morgner A, Dempfle A, Günther A, Liu H et al. Long-term follow-up of gastric MALT lymphoma after Helicobacter pylori eradication. J CLIN ONCOL. 2005 Nov 1;23(31):8018-24. https://doi.org/10.1200/JCO.2005.02.3903

Bibtex

@article{fd5d4aa68d2b47fa86c5dc096b1537f2,
title = "Long-term follow-up of gastric MALT lymphoma after Helicobacter pylori eradication",
abstract = "PURPOSE: Cure of infection induces remissions in most patients with early stage Helicobacter pylori- (Hp) positive gastric MALT (mucosa-associated lymphoid tissue) lymphoma (GML). We tracked the long-term stability of remissions in this prospective, multicenter trial.PATIENTS AND METHODS: In 120 patients with stage I(1E) disease, we performed sequential endoscopic-bioptic follow-up after Hp eradication and polymerase chain reaction of the rearranged immunoglobulin heavy chain gene. The status of t(11;18) was assessed in 65 patients.RESULTS: Median follow-up was 75 months (range, one to 116). Five-year survival was 90%. Eighty percent of patients (96 of 120) achieved complete histologic remission (CR). Eighty percent of CRs are in continuous complete histologic remission (CCR). Three percent of CR patients (three of 96) relapsed and were referred for alternative treatment. Seventeen percent of CR patients (16 of 96) showed histologic residual disease (RD) during follow-up; a watch-and-wait strategy was applied, and all entered into a second CR. After a median follow-up of 63 months, 14 of 52 analyzed patients reaching CR showed ongoing B-cell monoclonality. Fifteen percent of GMLs were t(11;18) positive. Both t(11;18) and ongoing monoclonality were associated with a significantly higher risk for no response or relapse (P =.004, P =.007), but also present in patients in CCR. Early gastric cancer was diagnosed in three cases during follow-up.CONCLUSION: Cure of Hp infection results in CCR in most patients. Histologic RD, B-cell monoclonality, and t(11;18) were present in a considerable number of CR patients. A watch-and-wait strategy is justified when close follow-up is guaranteed.",
keywords = "Adult, Aged, Aged, 80 and over, Anti-Bacterial Agents, Chromosomes, Human, Pair 11, Chromosomes, Human, Pair 18, Drug Therapy, Combination, Female, Follow-Up Studies, Gene Rearrangement, Helicobacter Infections, Helicobacter pylori, Humans, Immunoglobulin Heavy Chains, Lymphoma, B-Cell, Marginal Zone, Male, Middle Aged, Neoplasm Staging, Prognosis, Prospective Studies, Remission Induction, Stomach Neoplasms, Survival Rate, Time Factors, Translocation, Genetic, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't",
author = "Thomas W{\"u}ndisch and Christian Thiede and Andrea Morgner and Astrid Dempfle and Annette G{\"u}nther and Hongxiang Liu and Hongtao Ye and Ming-Qing Du and Kim, {Theo D} and Ekkehard Bayerd{\"o}rffer and Manfred Stolte and Andreas Neubauer",
year = "2005",
month = nov,
day = "1",
doi = "10.1200/JCO.2005.02.3903",
language = "English",
volume = "23",
pages = "8018--24",
journal = "J CLIN ONCOL",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "31",

}

RIS

TY - JOUR

T1 - Long-term follow-up of gastric MALT lymphoma after Helicobacter pylori eradication

AU - Wündisch, Thomas

AU - Thiede, Christian

AU - Morgner, Andrea

AU - Dempfle, Astrid

AU - Günther, Annette

AU - Liu, Hongxiang

AU - Ye, Hongtao

AU - Du, Ming-Qing

AU - Kim, Theo D

AU - Bayerdörffer, Ekkehard

AU - Stolte, Manfred

AU - Neubauer, Andreas

PY - 2005/11/1

Y1 - 2005/11/1

N2 - PURPOSE: Cure of infection induces remissions in most patients with early stage Helicobacter pylori- (Hp) positive gastric MALT (mucosa-associated lymphoid tissue) lymphoma (GML). We tracked the long-term stability of remissions in this prospective, multicenter trial.PATIENTS AND METHODS: In 120 patients with stage I(1E) disease, we performed sequential endoscopic-bioptic follow-up after Hp eradication and polymerase chain reaction of the rearranged immunoglobulin heavy chain gene. The status of t(11;18) was assessed in 65 patients.RESULTS: Median follow-up was 75 months (range, one to 116). Five-year survival was 90%. Eighty percent of patients (96 of 120) achieved complete histologic remission (CR). Eighty percent of CRs are in continuous complete histologic remission (CCR). Three percent of CR patients (three of 96) relapsed and were referred for alternative treatment. Seventeen percent of CR patients (16 of 96) showed histologic residual disease (RD) during follow-up; a watch-and-wait strategy was applied, and all entered into a second CR. After a median follow-up of 63 months, 14 of 52 analyzed patients reaching CR showed ongoing B-cell monoclonality. Fifteen percent of GMLs were t(11;18) positive. Both t(11;18) and ongoing monoclonality were associated with a significantly higher risk for no response or relapse (P =.004, P =.007), but also present in patients in CCR. Early gastric cancer was diagnosed in three cases during follow-up.CONCLUSION: Cure of Hp infection results in CCR in most patients. Histologic RD, B-cell monoclonality, and t(11;18) were present in a considerable number of CR patients. A watch-and-wait strategy is justified when close follow-up is guaranteed.

AB - PURPOSE: Cure of infection induces remissions in most patients with early stage Helicobacter pylori- (Hp) positive gastric MALT (mucosa-associated lymphoid tissue) lymphoma (GML). We tracked the long-term stability of remissions in this prospective, multicenter trial.PATIENTS AND METHODS: In 120 patients with stage I(1E) disease, we performed sequential endoscopic-bioptic follow-up after Hp eradication and polymerase chain reaction of the rearranged immunoglobulin heavy chain gene. The status of t(11;18) was assessed in 65 patients.RESULTS: Median follow-up was 75 months (range, one to 116). Five-year survival was 90%. Eighty percent of patients (96 of 120) achieved complete histologic remission (CR). Eighty percent of CRs are in continuous complete histologic remission (CCR). Three percent of CR patients (three of 96) relapsed and were referred for alternative treatment. Seventeen percent of CR patients (16 of 96) showed histologic residual disease (RD) during follow-up; a watch-and-wait strategy was applied, and all entered into a second CR. After a median follow-up of 63 months, 14 of 52 analyzed patients reaching CR showed ongoing B-cell monoclonality. Fifteen percent of GMLs were t(11;18) positive. Both t(11;18) and ongoing monoclonality were associated with a significantly higher risk for no response or relapse (P =.004, P =.007), but also present in patients in CCR. Early gastric cancer was diagnosed in three cases during follow-up.CONCLUSION: Cure of Hp infection results in CCR in most patients. Histologic RD, B-cell monoclonality, and t(11;18) were present in a considerable number of CR patients. A watch-and-wait strategy is justified when close follow-up is guaranteed.

KW - Adult

KW - Aged

KW - Aged, 80 and over

KW - Anti-Bacterial Agents

KW - Chromosomes, Human, Pair 11

KW - Chromosomes, Human, Pair 18

KW - Drug Therapy, Combination

KW - Female

KW - Follow-Up Studies

KW - Gene Rearrangement

KW - Helicobacter Infections

KW - Helicobacter pylori

KW - Humans

KW - Immunoglobulin Heavy Chains

KW - Lymphoma, B-Cell, Marginal Zone

KW - Male

KW - Middle Aged

KW - Neoplasm Staging

KW - Prognosis

KW - Prospective Studies

KW - Remission Induction

KW - Stomach Neoplasms

KW - Survival Rate

KW - Time Factors

KW - Translocation, Genetic

KW - Journal Article

KW - Multicenter Study

KW - Research Support, Non-U.S. Gov't

U2 - 10.1200/JCO.2005.02.3903

DO - 10.1200/JCO.2005.02.3903

M3 - SCORING: Journal article

C2 - 16204012

VL - 23

SP - 8018

EP - 8024

JO - J CLIN ONCOL

JF - J CLIN ONCOL

SN - 0732-183X

IS - 31

ER -